Catalyst Event
Johnson & Johnson (JNJ) · Other
From Akros U.S. Tech 100 Protective Allocation Monthly Index (A100PAM)
3/18/2026, 12:00:00 AM
The U.S. Food and Drug Administration (FDA) is expected to approve Icotyde (icotrokinra) on March 18, 2026, for treating moderate-to-severe plaque psoriasis; analysts forecast the drug to achieve blockbuster sales. High impact estimated due to significant revenue potential forecasted.
Korean Translation
2026년 3월 18일 미국 FDA의 아이코타이드(Icotyde) 승인이 예상됨. 분석가들은 이 약물이 블록버스터급 매출을 달성할 것으로 전망됨.
Related Recent Events
Meta Platforms Inc (META) · Other
Meta will officially shut down VR access to its social platform Horizon Worlds on June 15, 2026, as part of a strategic shift away from its initial metaverse vision. Low importance as this strategic shift is estimated to have >=1% price impact scheduled.
6/15/2026, 12:00:00 AM
Rocket Lab Corp (RKLB) · Earnings Release
Q1 2026 earnings release, which is estimated to have a medium impact due to typical price volatility surrounding financial reports, is scheduled.
5/14/2026, 12:00:00 AM
Biogen Inc (BIIB) · Earnings Release
Q1 2026 earnings release (Low impact estimated as routine earnings releases typically see at least 1% volatility) scheduled.
5/6/2026, 12:00:00 AM
Amazon.com Inc (AMZN) · Earnings Release
Amazon's Q1 2026 earnings release is scheduled. The company guided for net sales between $173.5 billion and $178.5 billion. Medium importance is estimated as earnings reports typically drive significant market volatility.
4/29/2026, 12:00:00 AM
Western Digital Corp (WDC) · Earnings Release
Western Digital is scheduled to report its Q3 2026 financial results on 2026-04-29, with analysts forecasting an EPS of approximately $2.30. A medium impact is estimated as quarterly results typically drive significant price movement, so the release is expected.
4/29/2026, 12:00:00 AM
Microsoft Corp (MSFT) · Earnings Release
Microsoft is expected to announce its fiscal year 2026 third-quarter financial results on April 28, 2026, with analysts forecasting an EPS of around $4.07. The earnings report is estimated to have a ~5% impact on the stock price; this result is forecasted.
4/28/2026, 12:00:00 AM